Doctor of Philosophy, The Ohio State University, 2010, Pharmacy
Natural products have played an important role in anticancer drug development for many decades. A recent review analyzing clinically approved anticancer drugs in Western countries and Japan during a twenty-five year period from 1981 to 2006 showed that, under the class of “non-biologicals/vaccines”, 63 of 81 (77.8%) anticancer drugs were either natural products or their derivatives, or synthesized molecules based on natural product pharmacophores. As part of a collaborative, multi-disciplinary approach to the discovery of new naturally occurring anticancer drugs, two medicinal plants, namely, Hyptis brevipes and Vitex quinata, collected in Indonesia, were selected for further investigation.
The chloroform-soluble extract of a sample of the entire plant of H. brevipes showed activity against the MCF-7 human breast cancer cell line. Bioassay-guided fractionation and purification of the CHCl3-soluble extract of H. brevipes led to the isolation of six new 5,6-dihydropyrone derivatives, namely, brevipolides A-F (342-346), together with seven known compounds. Brevipolides A-F (342-346), and a previously known 5,6-dihydropyrone derivative (347), were assigned with the absolute configuration, 5R, 6S, 7S, and 9S, as elucidated by analysis of data obtained from their CD spectra and by Mosher ester reactions. Brevipolides B and D, as well as compound 347 exhibited ED50 values of 6.1, 6.7 and 3.6 µM against MCF-7 cells. Brevipolides A, B, and F, and compound 349 (the known 5,6,3′-trihydroxy-3,7,4′-trimethoxyflavone) gave ED50 values of 5.8, 6.1 7.5, and 3.6 µM against HT-29 cells, respectively. However, no significant cytotoxicity was found against Lu1 cells for any of the compounds isolated. When these compounds were subjected to evaluation in a panel of mechanism-based in vitro assays, compound 347 were found to be active in an enzyme-based ELISA NF-κB p50 assay, with an ED50 value of 15.3 µM. In a mitochondrial transmembrane potential assay, brevioplide C, compounds 348 and (open full item for complete abstract)
Committee: A. Douglas Kinghorn PhD (Advisor); Esperanza Carcache de Blanco PhD (Committee Member); James R. Fuchs PhD (Committee Member); Pui-Kai Li PhD (Committee Member)
Subjects: Pharmaceuticals